ArticleNorthern clinics of Istanbul2022
Turkish validity and reliability of Type-1 Diabetes Stigma Assessment Scale.
Article in Northern clinics of Istanbul, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06850441 (Effects of Anti-Stigma Psychoeducation Based on Roy Adaptation Model on Stigma and Quality of Life in Individuals With Type 1 Diabetes), which is not on this map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effects of Anti-Stigma Psychoeducation Based on Roy Adaptation Model on Stigma and Quality of Life in Individuals With Type 1 Diabetes
Who cites it
1 citing paper in PubMed.
- Diabetes Stigma and Clinical Outcomes: An International Review.Journal of the Endocrine Society · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe objective of the study was to carry out validity and reliability of Type 1 Diabetes Stigma Assessment Scale (DSAS-1) in Turkish.
methodsThe methodological study was conducted between December 2017 and May 2019, with 147 patients with Type 1 diabetes who applied to the Endocrinology, Internal Medicine policlinics of a Training and Research Hospital. The data were collected with the Introductory Information Form and DSAS-1. SPSS-22 and Mplus Version-7.4 were used for data analysis. Validity (group-back translation method, Polit and Beck technique, factor analysis, and known-group comparison and pilot study) and reliability (test-retest reliability, Cronbach's alpha reliability coefficient, and item-total correlation) analyses were used.
resultsIt was found that 94.7% of the content validity index of the items of the DSAS-1 was 0.80 or above; the scale can factorable (Kaiser-Meyer-Olkin=0.86) and it was determined that the scale was able to separate known groups; the scale confirmed the 3-factor structure according to confirmatory factor analysis; the factor loads varied between 0.34 and 0.87 and their level was suitable according to fit index criteria (CFI=0.90, TLI=0.89, RMSEA=0.069, SRMR=0.065, Chi-square/df=1.706); the test-retest reliability value (r) was above 0.82; Cronbach's alpha coefficient of Turkish DSAS-1 was 0.89; and Cronbach's alpha coefficient of subscales was, respectively, to be 0.81, 0.80, and 0.81.
conclusionIt was found that the DSAS-1 has validity and reliability in Turkish and is a suitable measurement tool to evaluate the stigma by the individuals with a diagnosis of Type 1 diabetes in Turkiye.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.